Zoetis Inc. (ZTS) stock price, quote and key numbers

Updated 28 September 2026, 09:52 ET

Zoetis Inc. (ZTS) closed at $71.05 on 25 September 2026, up 1.1%. That leaves it down 0.5% over a week, down 8.3% over a month and down 49.8% over a year. It is at the bottom of its 52 week range of $69.52 to $148.79. The median analyst price target of $94 sits 33.0% above the close.

The price

Last close$71.05
Day+1.11%
1 week-0.49%
1 month-8.35%
3 months-6.62%
6 months-39.08%
Year to date-43.53%
1 year-49.85%
52 week high$148.79
52 week low$69.52
Volume4,166,940
Average volume, 3 months5,670,412
Market cap$29.0B

Changes compare dividend and split adjusted closes over trading sessions, so the one year figure is the last close against the close 252 sessions earlier. The 52 week range uses the daily highs and lows of the same window. Read the guide: How to read a stock quote.

The live price, the day's chart and the pre market and after hours prints are in the app: open ZTS in Just Stock Quotes.

Trend and range

ZTS trades below both its 50 day average of $74.93 and its 200 day average of $99.55, the shape of a downtrend. The 50 day average sits below the 200 day average. Its beta against the S&P 500 over the last year is 0.44, a stock that moves less than the market. It is 52.2% below its 52 week high and 2.2% above its 52 week low.

50 day average$74.93
200 day average$99.55
Above 50 dayNo
Above 200 dayNo
Beta, 1 year0.44
Range position2%

Moving averages smooth the closes of the last 50 and 200 sessions; being above or below them describes the trend, it does not predict it. Beta is how much the stock moved for each move in the S&P 500 over the year. Read the guide: Moving averages, the 52 week range and beta.

What analysts say

In the last 90 days 11 firms recorded 13 actions on ZTS: 12 kept a view and 1 downgrade. Price targets: 12 lowered. The most recent targets from 10 firms run from $80 to $115, with a median of $94, 33.0% above the last close.

Actions, 90 days13
Firms11
Median target$94
Median vs close+33.00%
DateFirmActionPrice target
25 Aug 2026TD CowenMaintains Buy$104.00 to $94.00
20 Aug 2026StifelMaintains Hold$85.00 to $80.00
11 Aug 2026CitigroupMaintains Buy$112.00 to $96.00
11 Aug 2026BNP ParibasMaintains Outperform$146.00 to $110.00
10 Aug 2026Piper SandlerMaintains Neutral$90.00 to $80.00
7 Aug 2026UBSMaintains Neutral$85.00 to $80.00

A target is one firm's guess at the price a year out, and the average runs optimistic. The useful reading is the mood: high targets and a wall of buys mean high expectations. Read the guide: What analyst ratings and price targets tell you.

Earnings

The next report is on the calendar for 5 November 2026 for Q3 2026, with earnings per share expected at $1.51. The last report, on 6 August 2026 for Q2 2026, showed EPS of $1.87 against $1.86 expected, a beat of 0.5%, on revenue of $2.5 billion. Zoetis Inc. beat the EPS estimate in 7 of its last 8 reported quarters.

Set a percent move alert before the report and the app pings you when the stock reacts, even after hours: open ZTS in Just Stock Quotes.

The numbers

Over the trailing twelve months Zoetis Inc. shows revenue growth of 1.58%, a gross margin of 71.67%, an operating margin of 37.13% and a return on equity of 64.91%.

MeasureValuePercentile
Revenue growth, TTM1.6%37th
Net income growth, TTM1.8%44th
Gross margin71.7%84th
Operating margin37.1%92nd
Free cash flow margin24.3%87th
Return on equity64.9%97th
Return on assets17.8%95th
Debt to equity2.8892nd
Current ratio3.0879th
Effective tax rate20.1%67th

The percentile ranks the company against every US company the data covers; a high percentile means most companies score lower.

Margins say how much of each dollar of sales becomes profit, returns say how hard the balance sheet works, and debt to equity says how much of it is borrowed. The valuation ratios, price to earnings and the rest, are in the app on the stock page. Read the guide: The valuation ratios on a stock page.

About Zoetis Inc.

Exchange
NYSE
Sector
Health Care
Industry
Pharmaceutical Products
Headquarters
Parsippany-Troy Hills, New Jersey
Chief executive
Kristin C. Peck
Employees
13,800
Website
zoetis.com

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts.

In the same sector

Other Health Care names in the S&P 500, by market cap:

LLY Eli Lilly & Co.JNJ Johnson & JohnsonABBV AbbVie Inc.MRK Merck & Co. Inc.UNH UnitedHealth Group Inc.TMO Thermo Fisher Scientific Inc.AMGN Amgen Inc.GILD Gilead Sciences, Inc.

Learn

Add ZTS to your watchlist, set a price alert, watch the live chart and ask FundSpec AI about it. No account, no subscription. The same screen is in the iPhone, iPad and Android apps.

Open ZTS in Just Stock Quotes